Skip to main content

1 Result(s)

within N M Brega Remove this filter

and

  1. Article

    Open Access

    A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

    Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients...

    E Boven, C Massard, J P Armand, C Tillier, V Hartog, N M Brega… in British Journal of Cancer (2010)

    Download PDF (407 KB) View Article